circRNA basic information
circBase ID: -
Name: hsa_circ_MYLK
Synonym: circRNA-MYLK
Host Gene: MYLK
Genomic location(hg19): -
Genomic location(hg38): -
Subcellular localization: not tested
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0004986
MONDO name: urinary bladder carcinoma
Disease details: bladder cancer / BCa
Disease DO ID:
 4007
Disease MeSH ID:
 -
Disease NCIt ID:
 C4912
Disease ICD11 ID:
 -
Disease OMIM ID:
 -
Species: Human
Species details: Homo sapiens
Tissue specimen:

bladder carcinomas; matched adjacent non-tumor tissues; matched para-carcinomas; xenograft tumor tissues; lung sections
Cell lines:

EJ; T24; 5673; BIU-87; SV-HUC-1; 293T; HUVECs
In vivo animal model:

cell line-derived xenograft
circRNA-disease information
Expression pattern:
UP
Associated gene: VEGFA, VEGFR2, Ras, Raf-1, MEK1/2, ERK1/2, AGO2, Snail, N-cadherin, Vimentin, E-cadherin, ZO-1, CD31, S100A4, Paxillin
Associated microRNA: miR-29a
Biological function: Promotes bladder cancer cell proliferation, migration, invasion, EMT, angiogenesis, xenograft tumor growth and metastasis; inhibits apoptosis when upregulated, while knockdown decreases proliferation and motility and induces apoptosis.
Molecular mechanism: circRNA-MYLK functions as a ceRNA/sponge for miR-29a, relieves miR-29a-mediated suppression of VEGFA, and activates VEGFA/VEGFR2 and downstream Ras/ERK signaling pathway.
Biological pathway or process:

VEGF/VEGFR (promotes); ERK (promotes); proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); EMT (promotes); angiogenesis (promotes); apoptosis (inhibits); ceRNA regulation (promotes); other pathway/process (promotes)
Detected method:
Q
H
M
Validation methods:

Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Microarray; RT-qPCR; FISH / smFISH; Clinical Sample Validation; Northern Blot; Transfection; CCK8; TUNEL; Wound Healing Assay; Transwell Assay; Tube Formation Assay; In Vivo Animal Model; H&E Staining; IF (Immunofluorescence); IHC (Immunohistochemistry); RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; EdU Staining; Annexin V/PI Flow Cytometry; Western Blot; ELISA; Survival Analysis; Cohort Study; Bioinformatics Analysis
Clinical significance:

circRNA-MYLK levels were related to progression of stage and grade of bladder carcinoma; elevated circRNA-MYLK expression was associated with poor survival; proposed as a promising target for BC diagnosis and therapy.
Description:

circRNA-MYLK is upregulated in bladder carcinoma and its high expression correlates with advanced clinicopathological features and poor survival. It promotes BC proliferation, migration, invasion, angiogenesis, EMT, xenograft growth and metastasis by sponging miR-29a, increasing VEGFA, and activating VEGFA/VEGFR2 and downstream Ras/ERK signaling.
Confidence score:

0.8743
Other information
Title:

Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway.

Journal: Cancer letters
Published: 2017
PubMed ID: 28687357
Study type:

combined biological and clinical study
Data availability: Supplementary Fig. S1; Supplementary Fig. S2; Supplementary Fig. S3; Supplementary Fig. S4; Supplementary Table S1; Supplementary Table
Code availability: -